Eyes on the Future: PVA-Hydrogel Lenses Paving the Way for Amphotericin B Ocular Delivery
drug delivery system; film hydrogel; contact lenses; ophthalmic therapy
Ocular diseases are a healthcare challenge due to their limited treatment options and reduced patient compliance, mainly in infectious conditions as fungal keratitis. Therefore, this study aimed to develop and characterize PVA-based hydrogel ophthalmic lenses (HOL) containing amphotericin B (AmB) as a potential approach for managing fungal ocular infections. To reach this goal, a central composite design (CCD) was carried out to develop HOL with desirable characteristics for ocular application. The formulations were evaluated regarding their thickness, swelling degree, molecular dynamics simulations (MDS), FTIR, crystallinity, in vitro degradability, drug loading and kinetic release. The CCD enabled the mathematical prediction of the swelling degree and its mechanisms, allowing the manufacturing of formulations with values of thickness and swelling degree with desirable characteristics for ophthalmic use. Results from FTIR and XRD indicated effective crosslinking, with AmB present in an amorphous form or molecular dispersion in the polymer matrix. Moreover, the HOL exhibited low in vitro degradability, reaffirming the effective-ness of the crosslinking process. The kinetic release studies confirmed that HOL controlled the re-lease of AmB. These results were corroborated by MDS studies, which revealed AmB formed stronger interactions with poly (vinyl alcohol) and sodium trimetaphosphate (STMP) when com-pared to water. The findings suggest that the developed HOL exhibit properties that make them a promising carrier for AmB ocular delivery.